DNMT3A

Across TCGA pan-cancer cohorts, DNMT3A mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated DNMT3A data layer compared with 28 for mass-spec protein and 9 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher DNMT3A mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated DNMT3A expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

CCRCC, PDAC, and LUAD are the cancer types where DNMT3A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	II,III,IV	0.868	0.594	.004	8	view →
PDAC	OS	Tertile	All	0.775	0.959	.034	6	view →
LUAD	DFS	Quartile	II,III,IV	0.686	0.301	.016	5	view →
HNSC	DFS	Tertile	III,IV	0.897	1.000	.019	3	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

DNMT3A–CCRCC (OS)

Open the CCRCC breakdown →